BioCurex Inc
(Public, OTC:BOCX)
http://www.biocurex.com/
BioCurex, Inc. ("BioCurex" or "the Company") is a biotechnology company developing products for cancerdiagnosis, imaging, and therapy that target a global oncology market forecast to reach over $50 billion by 2009. The Company uses a novel, patented technology based on the RECAF™ cancer marker, discovered by Dr. Ricardo Moro-Vidal, BioCurex's chief executive officer (CEO), president, and founder. RECAF™ is a molecule found on malignant† cells but absent from most normal or benign cells. BioCurex believes that the detection of this molecule in tissue or serum samples is the foundation for new cancer diagnostic tests and imaging techniques. The RECAF™ marker has been found on every cancer tissue that BioCurex has studied to date, including on many common, severe cancers: breast, lung, gastric, prostate, and leukemia. This characteristic indicates that RECAF™ is capable of detecting more than one type of cancer, which is a limitation of many currently available cancer markers. The Company's RECAF™ technology is reported to have high levels of 
clinical sensitivity and specificity (measures of cancer marker accuracy), successfully detecting over 90% of cancer in blood and tissue samples. A serum-based assay using RECAF™ recently identified twice as many prostate cancers as the current standard for prostate cancer detection, the prostate specific antigen (PSA) test. A RECAF™-based test also detected 90% to 93% of Stage I and Stage II (early stage) breast cancer samples, without any false positives. This data supports BioCurex's aim of reducing human suffering through the early detection of cancer or cancer recurrence after treatment. Moreover, due to its ability to differentiate between cancerous and normal cells, RECAF™ technology may facilitate the administration of targeted therapeutics that attack cancer cells but do not damage healthy tissue.
The current state of cancer detection
• According to the World Health Organization, the number of people diagnosed with malignant tumors will increase by 50% in a dozen years.
• Survival rates depend mostly on how early the disease is discovered. i.e.
